


# Journal Pre-proof

Provision of clinical pharmacy services during the COVID-19 pandemic: experiences of pharmacists from 16 European countries

Vibhu Paudyal, Cathal Cadogan, Daniela Fialová, Martin C. Henman, Ankie Hazen, Betul Okuyan, Monika Lutters, Derek Stewart



PII: S1551-7411(20)31202-X

DOI: <https://doi.org/10.1016/j.sapharm.2020.11.017>

Reference: RSAP 1699

To appear in: *Research in Social & Administrative Pharmacy*

Received Date: 12 September 2020

Revised Date: 25 November 2020

Accepted Date: 26 November 2020

Please cite this article as: Paudyal V, Cadogan C, Fialová D, Henman MC, Hazen A, Okuyan B, Lutters M, Stewart D, Provision of clinical pharmacy services during the COVID-19 pandemic: experiences of pharmacists from 16 European countries, *Research in Social & Administrative Pharmacy*, <https://doi.org/10.1016/j.sapharm.2020.11.017>.

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

© 2020 Elsevier Inc. All rights reserved.

### Author contributions

VP was the principal investigator of the study. All study authors are members of the European Society of Clinical Pharmacy Research Committee and jointly led the conception of the study. All authors were involved in the data collection by conducting interviews and conducting analysis of the transcripts. VP and CC led the drafting of the manuscript to which all authors contributed through editing and revision. All authors had access to the data sets and agreed to the final version of the manuscript.

Journal Pre-proof

## **Provision of clinical pharmacy services during the COVID-19 pandemic: experiences of pharmacists from 16 European countries**

Vibhu Paudyal\*<sup>1</sup>, Cathal Cadogan<sup>2</sup>, Daniela Fialová<sup>3,4</sup>, Martin C Henman<sup>5</sup>, Ankie Hazen<sup>6</sup>, Betul Okuyan<sup>7</sup>, Monika Lutters<sup>8,9</sup>, Derek Stewart<sup>10</sup>

<sup>1</sup>School of Pharmacy, University of Birmingham, Birmingham, United Kingdom

<sup>2</sup>School of Pharmacy and Biomolecular Sciences, Royal College of Surgeons in Ireland, Dublin, Republic of Ireland

<sup>3</sup>Department of Social and Clinical Pharmacy, Faculty of Pharmacy in Hradec Králové, Charles University, Czech Republic

<sup>4</sup>Department of Geriatrics and Gerontology, 1st Faculty of Medicine Charles University, Prague, Czech Republic

<sup>5</sup>School of Pharmacy and Pharmaceutical Sciences, Trinity College Dublin, Dublin, Republic of Ireland

<sup>6</sup>Centre for Pharmacy Postgraduate Education, University of Manchester, Manchester, United Kingdom

<sup>7</sup>Clinical Pharmacy Department, Faculty of Pharmacy, Marmara University, Istanbul, Turkey

<sup>8</sup>Clinical Pharmacy, Cantonal Hospital Baden, Baden, Switzerland

<sup>9</sup>Swiss Federal Institute of Technology, Zurich, Switzerland

<sup>10</sup>College of Pharmacy, QU Health, Qatar University, Doha, Qatar

\*Correspondence

Vibhu Paudyal, PhD

School of Pharmacy, College of Medical and Dental Sciences

University of Birmingham, Edgbaston, Birmingham,

United Kingdom B15 2TT

Tel: 0044-121 4142538

E-mail: [v.paudyal@bham.ac.uk](mailto:v.paudyal@bham.ac.uk)

### **Conflicts of interest**

There are no conflicts of interests to declare.

## **Provision of clinical pharmacy services during the COVID-19 pandemic: experiences of pharmacists from 16 European countries**

### **Abstract**

**Background:** The pharmacy profession has an important role in the frontline healthcare response to COVID-19 across all settings.

**Objective:** This study sought to explore the views and experiences of clinical pharmacists in relation to the provision of clinical pharmacy services during COVID-19.

**Methods:** Semi-structured qualitative interviews were conducted with pharmacists working in clinical roles in healthcare settings across Europe. Participants were recruited through professional organisations of clinical and hospital pharmacists combined with a snowballing technique. The Pharmacy Emergency Preparedness and Response Framework and Disaster Preparedness Framework for pharmacy services were used to generate data which were analysed using the thematic framework method.

**Results:** Twenty-two participants from 16 European countries described a range of measures to protect patients, public and healthcare staff against virus transmission including developing and disseminating educational materials. Most described their involvement in aspects of evidence provision such as facilitating clinical trials, gathering and appraising evidence and disseminating clinical information. Many hospital-based pharmacists were reassigned to new roles such as intensive care. Routine clinical services were extensively interrupted and remote forms of communication were used. Most were motivated by a strong sense of professionalism to continue delivering services. A number of facilitators and barriers to prevention, preparedness and response actions were identified which related to uptake of new roles, recognition of pharmacists roles in the healthcare team, information gathering, communication with patients and healthcare professionals, and provision of routine clinical services.

**Conclusions:** Participants in this multinational qualitative study described a range of service adaptations and adoption of novel roles to prevent and mitigate the public health impact of the pandemic. The study findings may help to inform governments, public health agencies and healthcare systems in harnessing ongoing service provision and adapt to any future interruptions.

**Key words:** COVID-19; Coronavirus; Pandemic; Pharmacist; Clinical Pharmacy; Pharmaceutical care

# 1 **Provision of clinical pharmacy services during the COVID-19 pandemic: experiences** 2 **of pharmacists from 16 European countries**

## 3 4 **INTRODUCTION**

5 COVID-19 is caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-  
6 CoV-2) and has been recognised as a global pandemic.<sup>1</sup> Since the first case was reported in  
7 the Wuhan province of China in December 2019, the virus has spread rapidly across the  
8 world with devastating impact on practically every aspect of daily life. As of 11<sup>th</sup> of  
9 September 2020, COVID-19 has infected over 28 million people worldwide and resulted in  
10 more than 900,000 deaths.<sup>2</sup> High rates of infection and deaths have been reported globally  
11 in many countries in Europe having experienced some of the highest mortality rates in the  
12 world including Italy, France and the United Kingdom.<sup>2</sup>

13  
14 Healthcare services across Europe have been severely impacted by COVID-19. At the early  
15 stages of the pandemic, various health services including hospital, community and primary  
16 care were restricted (e.g. non-urgent elective surgeries, routine health checks and  
17 medication reviews) to ensure adequate resources were in place to deal with patients  
18 presenting with COVID-19.<sup>3,4</sup> Following public health measures to suppress the spread of  
19 the virus (e.g. social distancing, wearing of face coverings), restrictions have now been  
20 eased to some degree in many countries. An additional challenge for healthcare services is  
21 dealing with the backlog of cases for non-COVID-19 related illnesses that did not present  
22 during the most severe stages of lockdown.<sup>5-7</sup> The delays caused by the pandemic to  
23 patients in seeking timely medical intervention will have a profound negative impact on  
24 health outcomes over the coming months and years. For example, a national population-  
25 based modelling study in England estimated increases in deaths due to cancer up to five  
26 years post-diagnosis ranging from 4.8% for lung cancer to 16.6% for colorectal cancer  
27 compared to pre-pandemic figures.<sup>8</sup>

28  
29 The pharmacy profession has had an important role in the frontline healthcare response to  
30 COVID-19. For many individuals with COVID-19 related queries or health concerns,  
31 community pharmacists may often be the first point of contact for reliable information and  
32 advice.<sup>9</sup> Community pharmacists have undertaken a range of roles and activities in response  
33 to the pandemic which include providing public health advice, information and education on  
34 personal and environmental hygiene, and making appropriate referrals in suspected cases of  
35 COVID-19.<sup>10</sup> Primary care-based pharmacists (i.e. those working in general practice) and  
36 hospital pharmacists have also undertaken various roles and activities spanning disease

37 prevention and infection control, provision of patient care and support to other healthcare  
38 professionals, as well sourcing and ensuring adequate supplies of medication.<sup>11</sup>

39

40 Although the scope and nature of their roles and clinical activities varies across settings and  
41 jurisdictions,<sup>12-14</sup> pharmacists' ultimate focus is on providing effective pharmaceutical care to  
42 improve health outcomes and quality of life for patients. In order to ensure evidence-based  
43 responses to future public health crises, it is also important to explore how clinical pharmacy  
44 services have adapted and responded to the pandemic.<sup>15</sup> This will help in identifying and  
45 sharing good practices, determining barriers and facilitators to service provision, as well as  
46 any lessons that can be learnt for future public health crises. However, a recent scoping  
47 review highlighted a deficit of studies to date examining core services provided by clinical  
48 pharmacists in various health settings in Europe during the COVID-19 pandemic.<sup>11</sup> The aim  
49 of this study was to explore the views and experiences of clinical pharmacists in Europe  
50 regarding their provision of clinical pharmacy services during COVID-19 with focus on  
51 prevention, preparedness and learning points for future public health crises.

52

## 53 **METHODS**

### 54 **Design**

55 This study consisted of semi-structured qualitative interviews with pharmacists working in  
56 clinical roles in various healthcare settings across Europe. The study is reported in  
57 accordance with the Consolidated Criteria for Reporting Qualitative studies (COREQ)  
58 checklist [Electronic supplemental material 1].<sup>16</sup>

59

### 60 **Sampling and recruitment**

61 A multi-strand sampling method was employed. Firstly, email invitations to take part in the  
62 study were issued to the membership of both the European Society of Clinical Pharmacy  
63 (ESCP) and European Association of Hospital Pharmacy (EAHP), and study information also  
64 included in the organisations' electronic newsletters. The ESCP is a professional network of  
65 clinical pharmacists across Europe which aims to promote, support, implement and advance  
66 education, practice and research in clinical pharmacy in order to optimise outcomes for  
67 patients and society.<sup>17</sup> The EAHP represents over 23,000 hospital pharmacists across  
68 Europe and seeks to develop the hospital pharmacy profession in order to continually  
69 improve the care and outcomes for patients in European hospitals.<sup>18</sup> Secondly, a  
70 snowballing technique was used to recruit additional participants known to ESCP and EAHP  
71 members who responded to the original invitation. Finally, members of the research team  
72 disseminated study information to their professional acquaintances with a view to achieving

73 a maximum variation sample in terms of practice setting (e.g. hospital, primary care) and  
74 speciality (e.g. respiratory, critical care) and country of practice.

75

76 In order to meet inclusion criteria, individuals had to work as a pharmacist in a clinical role in  
77 any healthcare setting in Europe. Individuals who were not practising as pharmacists in  
78 clinical roles Europe or could not communicate in English were not eligible to take part in the  
79 study. Pharmacists interested in participating in the study were asked to contact the principal  
80 investigator (XX anonymised) who emailed a study information sheet and consent form and  
81 arranged for a member of the research team to follow-up those agreeing to participate to  
82 schedule an interview. Sampling and recruitment proceeded until data saturation was  
83 achieved. No honorarium was provided for participating in the study.

84

### 85 **Data collection and analysis**

86 Interviews were conducted by members of the research team consisting of academic and  
87 clinical pharmacists (all with PhD level qualification) with extensive qualitative research  
88 experience. All interviews were conducted in English using online platforms Microsoft  
89 Teams, Skype and Zoom) and took place over June- July 2020. With participants' consent,  
90 each interview was digitally recorded and transcribed. Any identifiers were removed and an  
91 anonymous code was assigned to each participant.

92

93 The interview schedule (Electronic supplemental material 2) was developed using a  
94 combination of the Pharmacy Emergency Preparedness and Response (PEPR)  
95 Framework<sup>19</sup> and Disaster Preparedness Framework (DPF) for pharmacy services.<sup>20,21</sup> Key  
96 domains within the PEPR and DPF are defined under a) prevention/ mitigation actions to  
97 minimise transmission and ensure patient and staff safety, and b) preparedness of clinical  
98 pharmacy services to respond to the pandemic c) action-response and adjustments and d)  
99 recovery. Topic guide questions under the four domains were then constructed according to  
100 the research aim and objectives. The topic guide questions related to participant  
101 perspectives on the impact of the pandemic on patient care and population health  
102 interventions; adjustments and actions undertaken to mitigate the impact; knowledge and  
103 skills required and gained; and any learning points for the future. The topic guide was refined  
104 through discussions amongst the research team which included a range of clinical practice  
105 and research experiences and represented seven different countries within Europe.

106

107 The analytical process commenced during the transcribing process by listening to interview  
108 recordings and repeated reading of the transcripts, thereby allowing the researchers to  
109 familiarise themselves with the data. Data analysis was conducted in accordance with the

110 framework method<sup>22</sup> and adopted a deductive approach using pre-defined coding categories  
111 with data categorized into a matrix system in Microsoft Excel based on emergent themes  
112 and subthemes.<sup>22</sup> The construction of the initial thematic framework was guided by the  
113 PEPR and DPF.<sup>19-21</sup> Transcribed data from the first two interviews were first coded using the  
114 predefined coding framework. This framework was further refined through discussion within  
115 the research team before a final agreed version was applied in the analysis of the remaining  
116 transcripts. Key themes describing the data were listed in column headings within the Excel  
117 spreadsheet with relevant quotes from participants presented across rows. Two researchers  
118 independently analysed each transcript. The matrix system was reviewed in estimating the  
119 point of data saturation (i.e. the point at which no new information was identified). We  
120 focused on the range of experiences and stipulated examples on perceived impact on  
121 practice, mitigation measures, and action response and adjustments when estimating data  
122 saturation.

123

124 Ethical approval

125 Ethical approval was granted by the Ethics Review Panel, University of XXX (anonymised),  
126 United Kingdom (ERN\_20-0781).

127

## 128 **RESULTS**

129 Twenty-two pharmacists participated representing 16 different countries within Europe (table  
130 1). Participants represented hospital, community and primary care settings. Those within the  
131 hospital sector delivered a range of specialist clinical roles including intensive care medicine,  
132 respiratory and transplant medicine. Practice experience (i.e. years qualified as a  
133 pharmacist) ranged from 3 to 30 years (table1). Interviews lasted approximately 50 minutes  
134 on average.

135

136 Results from the framework analysis of themes and illustrative quotes are presented under  
137 the following key domains a) prevention/mitigation, b) preparedness c) action-response and  
138 adjustments d) recovery and e) reflection of personal experience. Barriers and facilitators  
139 specifically relating to ensuring adequate prevention/mitigation, preparedness and action-  
140 response and adjustments are presented throughout and summarised in table 2.

141

### 142 **A. Prevention/Mitigation**

#### 143 **Reducing the health risks posed by COVID-19**



144 Participants described a range of prevention and mitigation measures to reduce the spread  
145 of COVID-19. These included adoption of social distancing, increased sanitisation and hand  
146 hygiene practices. Facilities were rearranged to ensure limited personnel and patients in  
147 clinical and office spaces as well as waiting areas. For example, community pharmacies  
148 described using 'night time' windows, purposefully-built hatches and cashless transactions to  
149 serve patients and customers. Such adjustments were made using community pharmacy's  
150 own resources as no external funding was received.

151 'Because when the pandemic started in Estonia, which was officially on March 12th we  
152 decided to close the doors of the pharmacy and dispense the medications and consult  
153 the patients through the small window like we do it at night.' Community pharmacist,  
154 Estonia

155 Some participants from hospital settings described facing difficulties in adjusting the facilities to  
156 ensure socially distanced services due to a lack of adequate space.

157 Patients were provided with protective masks upon entering clinical facilities. Some participants  
158 noted that sanitizing chemicals, wipes and personal protective equipment (PPE) were not in  
159 adequate supply at the beginning of the pandemic. Many pharmacists reported being unsure  
160 about how to effectively use PPE which in a number of cases was attributed to a perceived lack  
161 of training.

162 'The personal protective equipment was not enough and not adequate all the time. They  
163 hadn't got enough quality [either] ... We did not know how to use the personal protective  
164 equipment.' Clinical Pharmacy Resident, Hospital, Turkey

### 165 **Educating the public on reducing the spread of COVID-19**

166 Many participants described being actively involved in directly educating patients and  
167 members of the public about social distancing, correct use of PPE and preventing the spread  
168 of COVID-19. This included verbal advice, information provision through social media and  
169 the development of educational material. Advice provision on the use of analgesics in  
170 COVID-19 was frequently mentioned. Some participants however, described the challenges  
171 they faced in educating the public.

172 'They thought we were exaggerating. And some of them even told me: "Why are you  
173 spreading the panic?" I answered: "I am not spreading the panic; ...everybody should act  
174 according to these rule". But you know, they did not perceive it as a threat at all. They  
175 perceive it just as additional burden or something unnecessary.' Community pharmacist,  
176 Croatia

**177 B. Preparedness**

178 Participants described a range of activities relating to preparedness for COVID-19. These  
179 included measures to ensure that effective response systems were in place by adjusting the  
180 physical layout and infrastructure including risk stratification, deployment of pharmacist  
181 across clinical settings, adjustment of working hours, staff leave, testing staff for COVID-19  
182 and utilising healthcare students to assist with the services.

**183 Adjusting physical facilities**

184 Participants from hospital pharmacy described the segregation of facilities to care for  
185 COVID-19 patients, high risk patients and those who were non-infected or at of low risk. For  
186 many, the early outbreak in Italy allowed some time to prepare and adjust their physical  
187 facilities to respond to COVID-19. Examples of physical facility adjustments included a  
188 separate hospital for COVID-19 patients, separate wards or even turning a cafeteria into an  
189 intensive care unit (ICU).

190 '...so the hospital is divided into green, amber and red zones. ...Red section which would  
191 be ICU and also anywhere there would be active aerosol generating procedures...and  
192 that would be the full gown over your scrubs, hat, mask and visor... we closed our  
193 canteen and turned it into a temporary ICU and we've put like a marquee at the front of  
194 the hospital where everyone goes for food.' Cardiology pharmacist, hospital, Northern  
195 Ireland

**196 Maintaining safe staffing levels**

197 Participants in the hospital sector described redeployment of clinical pharmacy staff from  
198 other clinical areas to COVID-19 wards and ICUs. While some participants described  
199 receiving some training prior to their deployment, others learnt while in practice.

200

201 'People just got on with it. More staff went into critical care and they needed training.'  
202 Hospital pharmacist, cardiology and pharmacy management, Republic of Ireland

203

204 Some participants reported that accommodation and shuttle transport services were  
205 provided to minimise transmission amongst healthcare staff. Some participants reported  
206 being asked to work from home, particularly those with young children and vulnerable family  
207 members. While this aimed to ensure social distancing and minimised transmission within  
208 the clinical setting, some participants were unhappy with their new working arrangements.

209 'I was annoyed that I was not allowed to run an inter-professional clinical meeting  
210 face to face in June. It had to be via Zoom. I was the only one from the practice that

211 was still working remotely from home. I felt lonely.’ Clinical pharmacist, Primary Care,  
212 the Netherlands

213 Many participants described having their work hours adjusted including reduced number of  
214 days but longer hours or alternate work days. Some noted that all annual leave was  
215 cancelled and this often led to low staff morale.

216 ‘Not getting to take any annual leave and not getting a break would just cause a lot of  
217 sickness and things like that. So the four days off (three days in) was good in terms of  
218 maintaining resilience’ Specialist respiratory pharmacist, hospital, England

219 A community pharmacy owner reported that many locum pharmacists cancelled their shifts  
220 which led to difficulty sourcing the required personnel to ensure safe operation of the  
221 community pharmacy. Some participants described getting students to help out to ensuring  
222 adequate staffing while others had to send students home to ensure safe staffing levels.

223 Participants from community pharmacy also described that adjustments in community  
224 pharmacy opening hours were enabled by the government which allowed them to operate  
225 limited hours to minimise staff burnout and fatigue. However, some primary care  
226 pharmacists noted that this caused issues in timely supply of medicines to the patients

### 227 **Testing staff for COVID-19**

228 While participants noted that staff testing for COVID-19 was not made available at the earlier  
229 stages of the pandemic, the situation was perceived to have improved over time. Many relied  
230 on the emergence of symptoms before isolating.

231 ‘We had no tests, we had only a few testing sets. So, nobody knew the situation..... and  
232 it did not allow us to really measure the risks and benefits of our interventions  
233 [preventative measures].’ Intensive Care Unit, hospital, Czech Republic

### 234 **C. Actions –response and adjustments**

235 Various actions in relation to responses and adjustments to routine clinical practice were  
236 described.

237

### 238 **Ensuring uninterrupted supply of medications and business continuity**

239 Most participants described shortages of medical supplies during the early phase of the  
240 pandemic. Medical supply shortages in ICUs were a particular issue. Participants mentioned  
241 borrowing stocks from other wards, departments, hospitals and other healthcare facilities.  
242 Such stock transfer was often organized by professional organisations or governmental

243 bodies. Some used their aseptic laboratories to prepare formulations to make up for the  
244 shortfall.

245

246 'We had a brief moment where propofol was an issue because they used it a lot for the  
247 corona [COVID-19] patients mostly in intensive care...but they managed to distribute  
248 from the main pharmacy...I needed to call them every other day for propofol.' Pharmacy  
249 department manager, hospital, Denmark

250

251 Some participants reported having had 'very good' business continuity plans and described  
252 having received excellent support from their government in ensuring adequate medical  
253 supplies and having 'never' faced shortages.

254

255 Hospital-based participants described ordering medicines such as hydroxychloroquine for  
256 the first time and this led to procurement challenges. Rationing of medicinal supplies as well  
257 as supplies of PPE and disinfectants was implemented throughout all stages.

258

259 Participants from community pharmacy described high demand for repeat prescriptions and  
260 over the counter (OTC) analgesics, vitamins, particularly vitamin C and OTC products  
261 claiming to boost the immune system. Temporary restrictions were implemented to address  
262 the situation. Some community pharmacist participants described repackaging bigger packs  
263 into smaller packs to ensure equitable supply. Some reported being allowed to extend the  
264 supply of repeat prescriptions without needing additional authorisation from the prescriber.  
265 Therapeutic substitutions were often exercised due to supply issues across all settings.

266

267 'People wanted the same brand name and we ran out. When the pandemic started  
268 people were buying 10 packages or 100 tablets of paracetamol per person. And one  
269 important change what was made in Estonia by our minister was that every person could  
270 buy only 2 packages of OTC medication and people didn't understand why...Patients  
271 were at first shocked [about therapeutic substitutions for prescribed medicines], but then  
272 they became very cooperative.' Community pharmacist, Estonia

273

#### 274 **Impact and adjustment of routine clinical practice**

275 Participants described the enormous impact of COVID-19 on routine clinical practice.  
276 Routine and non-urgent appointments in hospitals were cancelled and participants described  
277 seeing unusually low number of patients for routine admissions. Many deemed that patients  
278 were often fearful of using healthcare services and that overcoming such fears was  
279 challenging.

280

281 Participants in the primary care settings reported that they could no longer offer blood  
282 pressure, temperature, oxygen saturation and cholesterol testing and had to advise patients  
283 to buy home testing kits. Reductions and adjustments of routine activities such as medicine  
284 use reviews and medicine reconciliations were noted and many were conducted over the  
285 phone.

286

287 'I was used to do domiciliary reviews or to see the patients at the surgery and they often  
288 brought their medicines with them. I was a bit pessimistic to start with. I thought that this  
289 was not the way to do medication reviews. But actually, it is going really well via phone.  
290 People can explain their symptoms very well over the phone, have their medications next  
291 to them, and are surprisingly open about sensitive topics.' Clinical pharmacist, Primary  
292 Care, the Netherlands

293

294 Many noted that the cancellation of routine clinical services created difficulties in ensuring  
295 that patients received appropriate monitoring and follow up.

296

297 'The biggest change was the clinics, because I do asthma clinics, which are quite hands  
298 on, checking their peak flow, doing spirometry, I'd be listening to their chest you think  
299 they are having an exacerbation. When they come in it is all visual, you can see how they  
300 walk how they talk, you observe them. And all these things are lost. I found that it was  
301 really hard.' Clinical pharmacist, general practice, England.

302

### 303 **Communicating with patients and healthcare professionals**

304 Remote forms of communications including web-based services were used extensively by  
305 participants to communicate with patients and other healthcare staff. Many however  
306 described that online platforms were overloaded. Remote communications were deemed to  
307 have caused issues in communicating with patients with low health literacy as well as older  
308 and disabled patients, immigrant communities with interpreter needs and those without  
309 access to the online communication facilities.

310

311 Many noted that PPE created communication challenges to offering the same level of patient  
312 care and experience.

313

314 'Many patients are old, they have hearing problems, they have problems with their vision,  
315 they do not understand what you are saying, especially when you wear masks and they

316 do not see your lips. So I had to write down what I wanted to say'. Community  
317 pharmacist, Croatia

318 Some perceived remote forms of communications being less effective in providing  
319 recommendations to doctors and some needed intensive follow up to make sure that their  
320 advice was accepted by the doctors.

321  
322 'I've realized that the acceptance rate of the interventions went down. I really had to  
323 follow up on the patients to make sure that the interventions were accepted. That was  
324 more time intensive.' Hospital pharmacist (general), Switzerland

325

### 326 **Advocating pharmacy's role and being a source of information for doctors**

327 Many participants reported offering information to doctors during the pandemic by searching  
328 and appraising guidelines, particularly in relation to the experimental drug treatments  
329 including hydroxychloroquine and remdesivir. Many described that the pandemic offered the  
330 opportunity to showcase their expertise as pharmacists.

331

332 'Doctors/colleagues see me as someone who provides the medicine information and of  
333 course critically appraise elevating literature, [e.g.] what is known about remdesivir etc.,  
334 Although clinical pharmacists are not recognized enough in my country, I think this period  
335 maybe will leave a better recognition for clinical pharmacists and pharmacists as  
336 medicinal experts.' Liver transplant pharmacist, hospital, Serbia

337

338 However, not everyone agreed that pharmacists were well recognised. Participants  
339 particularly from primary care felt that they were left out of care and planning activities during  
340 initial phase of the crisis.

341

342 'The first two weeks were very unsettling. I felt like I was in a sort of identity crisis.' I felt  
343 like we [primary care pharmacists] are useless, not necessary anymore. Everyone was  
344 working around the clock at the front line, who cares about my job? But that turned out  
345 differently, at least for patients. We developed protocols to provide care remotely and  
346 patients really appreciated this.' Clinical pharmacist, general practice, the Netherlands.

347

348 One participant mentioned that the same PPE and colour of uniforms being worn during the  
349 pandemic levelled the hierarchy and therefore everyone was 'seen as equal'.

350

### 351 **Taking care of COVID-19 patients**

352 Some participants described being directly involved in the care of COVID-19 patients.  
353 Participants described a lack of information during the early phase of the pandemic and had  
354 to extensively search the literature to source the information they were looking for. Many  
355 reported attending several webinars in some days. Others described relying on medical  
356 journals as well as World Health Organisation (WHO) and local hospital guidelines. Some  
357 admired the promptness at which information was made available by the professional  
358 societies (such as the EAHP) and public health agencies. However, some participants  
359 described the confusion created by different guidelines and their interpretation by different  
360 clinical departments.

361  
362 'It was also really hard to understand who is doing what and when due to guidelines  
363 changing hour to hour...the physicians got one guideline then the nurses got another  
364 then we got another and these guidelines didn't speak in the same direction at all so that  
365 did something for the collaboration in multidisciplinary teams.' Pharmacy department  
366 manager, hospital, Denmark

367

#### 368 **D. Recovery and returning to normal**

369 Most participants were still adjusting and coping with the pandemic. However many noted  
370 that they were anticipating that the virus would remain in the community for the foreseeable  
371 future and that social distancing measures would remain common practice. Many believed  
372 that telecommunications and web-based communications would remain part of work  
373 practices in the future. Those working with high risk patients such as in the transplant and  
374 immunotherapy departments considered that current social distancing measures shall  
375 remain in place.

376

377 Community pharmacists identified opportunities for more clinical screening and interventions  
378 in the future, particularly as many patients considered visiting their GPs less preferable.

379

380 'In Spain it is not really easy to go to the General Practitioner, so we have increased the  
381 number of people who actually come to pharmacy to know their cardiovascular risk and  
382 then we take more glycosylated haemoglobin, the lipid profile, the blood pressure and so.  
383 I think that these services have gained importance and strengthen here the role of  
384 pharmacists. We really want to keep these services in the future.' Community  
385 pharmacist, Spain

386

387 Participants in the community also described their readiness to offer vaccinations for COVID-  
388 19 once available/approved and other currently available vaccinations (e.g. influenza).



389

390 'pharmacist can be very important and active in promoting vaccination, for COVID or  
391 other diseases.' Clinical Pharmacy healthcare solutions designer, Portugal

392

### 393 **E. Reflection on personal experience**

394 Most participants described feeling proud to serve their communities and countries at this  
395 time of need. They considered it a professional and ethical responsibility.

396 'I felt it as my professional and human responsibility. I think it was something that was not  
397 even negotiable, I felt this is my responsibility.' Liver transplant pharmacist, hospital,  
398 Serbia

399 Measuring success and failures of responsive actions were often based on how such actions  
400 helped patients and ensured a safe working environment for participants and other  
401 healthcare professionals. Those directly responsible for the care of COVID-19 patients  
402 reported that seeing patients being discharged from the hospital was a great motivation.

403

404 'So being able to help with that was really good and even little things like seeing how  
405 many patients have been discharged from hospital with coronavirus compared to the  
406 amount of deaths and was really good to see.' Specialist respiratory pharmacist, hospital,  
407 England

408 Participants reflected on the experiences and skills developed during the crisis thus far. They  
409 felt that the pandemic brought people from different disciplines and pharmacy colleagues  
410 together to look after each other, as well as their patients.

411

412 'Used to high risk patients. Used to people dying. How fast it came and too much and too  
413 little information at same time. Every day something changed...traumatic at speed of  
414 complications and death of patients...uncertainty and worry about colleagues...trying to  
415 look after each other all the time. Worried about ...bringing it [the virus] home to family.  
416 Worried about staff member with four small children who caught it.' Cardiology  
417 pharmacist, hospital, Republic of Ireland

418

419 All participants felt that providing care during the pandemic was challenging but rewarding.  
420 Participants in the hospitals mentioned that they were able to develop new skills relating to  
421 critical care, extemporaneous compounding and clinical trials medicine. Other skills  
422 mentioned by participants included remote communications, time management, resilience  
423 and the ability to work under pressure.



424

425 'Well, I would only say that providing limited clinical pharmacy services in my own  
426 environment will be improved based on our current experience, which will basically be  
427 focused on better communication, better supervision on treatments and maybe more  
428 efficient communication, when there is another wave or another peak of Covid-19  
429 pandemic.' Orthopaedic surgery pharmacist, hospital, Serbia

430

## 431 **DISCUSSION**

432 To our knowledge, this is the first multinational study on the delivery of clinical pharmacy  
433 services, and associated adaptations, during the COVID-19 pandemic. Qualitative data were  
434 obtained from 22 pharmacists from 16 different European countries representing a diverse  
435 range of clinical settings, specialities and experiences in response to aspects of protection,  
436 preparedness and planning during the ongoing pandemic. Pharmacists adapted their  
437 existing roles and implemented innovations to existing work practices in order to counter the  
438 challenges presented by COVID-19. Many described working to the best of their abilities to  
439 ensure that clinical pharmacy services were uninterrupted insofar as possible at the time of  
440 critical need. Many clinical pharmacists (particularly in primary care and community settings)  
441 became the first point of contact for patients with the healthcare systems particularly where  
442 GP services were operating at reduced capacity or even locally unavailable. Participants  
443 described that they were motivated by a strong sense of professionalism and desire to  
444 deliver services for the sake of humanity, taking pride in what they had achieved and the  
445 value placed in them by patients and other health professionals.

446 Many measures were adopted in an attempt to protect against transmission of the virus. A  
447 previous study in Kosovo involving community pharmacists reported that implementation of  
448 preventative measures was associated with respondents' perception that pharmacists and  
449 the pharmacy profession were valued more by patients and other health professionals.<sup>23</sup>  
450 However, pharmacies received no external funding support to adopt such preventative  
451 measures, similar to the experiences faced by our study participants. Key barriers to  
452 pharmacy activities included the requirements to restructure the physical environment to  
453 ensure social distancing. Pharmacists described being involved in the development and  
454 dissemination of educational materials and offering verbal advice to patients, members of  
455 the public and health professionals.

456 Some described facing challenges to counter misinformation in social media as well as the  
457 difficulty in dealing with constantly changing advice and evidence. While there have been  
458 recent efforts by World Health Organisation working with technology companies in fighting

459 the 'infodemic'<sup>24</sup> pharmacists are likely to encounter patients who have been misinformed by  
460 false information. A previous study conducted in the community pharmacy setting suggests  
461 that vast majority of pharmacy clientele lack skills in critically interpreting information about  
462 their illness and medicines.<sup>25</sup> In the context of new disease such as COVID-19, such  
463 misinformation is likely to negatively influence patients' self-management and care seeking  
464 behaviours. Pharmacists will have important roles in continuing to counter the misinformation  
465 for the duration of the COVID-19 pandemic<sup>26</sup> including the development of credible and  
466 reliable pandemic-specific information resources for the general public.<sup>27</sup>

467 Many participants, particularly those from hospital settings, described being involved in the  
468 delivery of new clinical roles. A number of participants were reallocated to the care of ICU  
469 patients. While some received training, albeit limited, others had to learn and adapt as they  
470 gained experience resulting in rapid expansion of their existing knowledge and skills. While  
471 continuing professional development (CPD) is mandatory for pharmacist registration in many  
472 countries, the planning of CPD is normally systematic and not time pressured.<sup>28</sup> Study  
473 participants reported being able to adjust current clinical services and innovate where  
474 necessary within a very short time period. This is an important learning point for future  
475 service interruptions and adaptations, as well as the sustainability of such services.  
476 Facilitation of clinical trials, intensive care medicine and extensive involvement in the  
477 retrieval of evidence-based literature to inform clinical practice of their own and other  
478 healthcare professionals were some of the stipulated examples.

479 Service adaptation to the pandemic had major consequences for routine clinical services  
480 across all settings. Many described that patient care could not be provided to groups of  
481 patients and that for others there were adaptations to specific activities such as routine  
482 monitoring of clinical biomarkers. However, several participants highlighted opportunities to  
483 enhance their clinical services as many patients were reluctant to use primary care general  
484 practice services due to fear of being contracting the virus. This increased focus on  
485 community pharmacy based clinical care is in line with the strategic developments in  
486 countries such as the UK.<sup>17</sup>

487 Most participants considered that other healthcare professionals appreciated and valued  
488 pharmacists' expertise and skills in their contributions to the clinical care of COVID-19  
489 patients or for other associated responses. Many described that the pandemic offered the  
490 opportunity to showcase the profession to other healthcare professionals particularly their  
491 expertise in the provision of new clinically relevant information, adjustments of clinical  
492 pharmacy services to accommodate digital communication as well as better prioritization of  
493 patients in need of relevant services. Previous literature suggests that the opportunity for

494 physicians and pharmacists to work together in a ward is an important facilitator for  
495 interprofessional collaboration.<sup>29</sup>

496 The use of remote communications to provide clinical services, both with patient and other  
497 healthcare professionals was also a key adjustment to the delivery of pharmacy services.  
498 Many valued the opportunities to communicate remotely through telephone and digital  
499 services. However, others reported that remote communication methods did not offer the  
500 same opportunity to interact with and monitor patients. Previous systematic reviews suggest  
501 that clinical pharmacist-led telemedicine services can improve clinical outcomes in patients  
502 with chronic disease<sup>30</sup> and effectively deliver public health services such as vaccinations,  
503 smoking cessation, hypertension management, and medication adherence and  
504 counselling.<sup>31</sup> Given that many participants in this study identified that there will be greater  
505 utilisation of remote communications in the future, healthcare systems should look into  
506 investing in digital communications and telemedicine platforms in the context of clinical  
507 pharmacy services.

#### 508 Strengths and limitations

509 To our knowledge, this is the first multi-national study investigating pharmacists' experiences  
510 of their responses to COVID-19. The study addresses a recognised gap in the literature.<sup>15</sup>  
511 The interview topic guide was developed using the PEPRF<sup>19</sup> and DPF<sup>20</sup> for pharmacy  
512 services. This enabled a detailed exploration of pharmacists' preparation and response  
513 activities in relation to COVID-19. Participants represented a range of practice setting,  
514 clinical expertise and experiences. Although our recruitment strategy did not aim for a quota  
515 sampling, diverse range of countries in relation to demography, timing of the first wave of  
516 COVID-19 pandemic (i.e. early vs late) and mortality rates were represented. Data analysis  
517 was conducted independently by two members of the research team using the framework  
518 method<sup>22</sup> which ensured a comprehensive and robust analysis, as well as the  
519 trustworthiness of the findings.<sup>32</sup> In terms of limitations, it must be noted that due to the  
520 adoption of qualitative design, the study findings may not be generalizable to all pharmacists  
521 and pharmacy services. The study did not investigate in-depth, the impact of national or local  
522 healthcare systems on participant responses to the pandemic and as such country specific  
523 research to promote best practices is needed. Due to time constraints, the interview  
524 schedule was not piloted or externally validated. However, the research team included a  
525 range of clinical practice and research experiences across seven different countries within  
526 Europe which allowed evaluation of face and content validity of the interview schedule within  
527 the research team. In addition, while estimating data saturation, we primarily focused on the  
528 range of examples in relation preparedness, prevention, actions response and adjustments.

529 Our approach to estimation of data saturation did not cover clinical setting specific barriers  
530 and facilitators.

531 Recommendations for practice and research

532 The facilitators and barriers to effective preparedness and response to the pandemic as  
533 identified in this study needs to be harnessed and addressed respectively. Pharmacists in  
534 diverse clinical settings can benefit from training to deliver pharmaceutical care services in  
535 critical care areas in preparedness to public health crises such as the ongoing pandemic as  
536 many participants had to undertake new roles without adequate education and training.  
537 Facilitators and barriers of practice changes as reported in the context of other clinical  
538 pharmacy services such as provision of public health interventions and supply of newly  
539 approved medicines in clinical practice are likely to be applicable.<sup>33,34</sup> Pharmacy  
540 educational curricula should also incorporate aspects of global health and pandemic  
541 preparedness.<sup>35</sup> Pharmacists' expertise and skills should be harnessed to enable them to  
542 source and critically appraise evidence-based information by providing relevant continuous  
543 professional development opportunities. While accessing and interpreting information from  
544 established drug information sources are recognised and expected skills of pharmacists,  
545 sourcing information from research databases and journals may often not be routine  
546 practice. A list of recommendations for health systems and services have been summarised  
547 and presented in table 3.

548 Participants reported that clinical pharmacy services including medicines were rationed to  
549 address staff shortages during the pandemic. Developing strategies to protect supply levels  
550 in anticipation of the future public health crises would benefit practice and patients.  
551 Governments and healthcare agencies should utilise clinical pharmacists in gathering  
552 intelligence around the lists of medicines that are at risk of shortages. Pharmacists should be  
553 trained to enable therapeutic substitutions at the time of medicines shortages.

554 Remote communication systems need to be strengthened to allow better communication  
555 between pharmacists and patients, as well as other health care professionals. Remote  
556 means of communications and telemedicine should cater for patients with low literacy, low  
557 cognitive functions, older patients and those with the need for interpreters as indicated by  
558 many participants in this study. Novel technologies should be harnessed to facilitate effective  
559 communications while pharmacists are using PPE.

560 Government and healthcare agencies should utilise pharmacists in the delivery of  
561 vaccinations and new medicines to provide protection and treatment. Pharmacists' routine  
562 clinical services such as provision of information on effective, cost-effective and safe drug

563 use, dispensing of medicines, minor ailments services and prescribing activities should be  
564 supported during the ongoing pandemic. In addition, government and healthcare agencies  
565 should ensure that the new knowledge and skills gained during the pandemic should be  
566 maintained and passed on to new practitioners.

567 Future research should identify the impact of the pandemic on clinical pharmacy services on  
568 patients, healthcare resources and cost-related outcomes. Further in-depth studies need to  
569 be conducted in various settings to identify context specific facilitators and barriers to clinical  
570 pharmacy service provision. Case study investigations should be conducted to identify and  
571 share best practices.

## 572 **Conclusions**

573 This multi-national study of clinical pharmacists' views and experience around prevention,  
574 preparedness and response to COVID-19 has identified pharmacists' diverse contributions  
575 to patient care and the education of other healthcare professionals and members of public.  
576 Key clinical pharmacy contribution areas include direct clinical care of COVID-19 patients;  
577 gathering and appraising evidence to inform patients and healthcare professionals; ensuring  
578 uninterrupted supply of medicines in the hospitals and community through effective  
579 procurement, planning, dispensing and supply of medicines, and by making therapeutic  
580 substitutions where necessary; providing clinical pharmacy services to high-risk populations;  
581 and adopting new digital communication with healthcare professionals and patients.  
582 Government and public health agencies should harness the facilitators and address the  
583 barriers to the provision of clinical pharmacy services as reported in this study. Future  
584 research should include outcome evaluations to examine the effectiveness of adapted and  
585 novel services in the context of the pandemic, including remote clinical pharmacy services.

## 586 **Acknowledgements**

587 The authors are grateful to all of the participants who contributed to this study. The authors  
588 would also like to acknowledge the European Society of Clinical Pharmacy and European  
589 Association of Hospital Pharmacy for their assistance in recruiting study participants. We  
590 would also like to thank University of XXX (anonymised) who is the lead sponsor of this  
591 study and facilitated the ethical review and research governance including storage and  
592 archiving of the datasets.

## 593 **Funding**

594 This research did not receive any specific grant from funding agencies in the public,  
595 commercial, or not-for-profit sectors.

## 596 REFERENCES

- 597 1. World Health Organization. WHO Coronavirus disease 2019 (COVID-19) Situation Report- 52.  
598 [https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200312-sitrep-52-covid-](https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200312-sitrep-52-covid-19.pdf?sfvrsn=e2bfc9c0_4)  
599 [19.pdf?sfvrsn=e2bfc9c0\\_4](https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200312-sitrep-52-covid-19.pdf?sfvrsn=e2bfc9c0_4). Accessed September 11, 2020.
- 600 2. John Hopkins University Coronavirus Resource Centre. Mortality analysis.  
601 <https://coronavirus.jhu.edu/data/mortality> . Accessed September 11, 2020
- 602 3. Rimmer A. Covid-19: GPs can stop health checks for over 75s and routine medicine reviews. *BMJ*.  
603 2020;368: m1157. [https://doi: https://doi.org/10.1136/bmj.m1157](https://doi.org/10.1136/bmj.m1157)
- 604 4. Iacobucci G. Covid-19: all non-urgent elective surgery is suspended for at least three months in  
605 England. *BMJ*. 2020;368:m1106. <https://doi.org/10.1136/bmj.m1106>
- 606 5. Rosenbaum L. The Untold Toll - The Pandemic's Effects on Patients without Covid-19. *N Engl J*  
607 *Med*. 2020;382:2368-2371. <https://doi.org/10.1056/NEJMms2009984>
- 608 6. Mahase E. BMA urges plan to tackle backlog of patients awaiting non-covid treatment. *BMJ*.  
609 2020;369:m2238. <https://doi.org/10.1136/bmj.m2238>
- 610 7. Helsper CW, Campbell C, Emery J, et al. Cancer has not gone away: A primary care perspective to  
611 support a balanced approach for timely cancer diagnosis during COVID-19. *Eur J Cancer Care*.  
612 2020;00:e13290. <https://doi.org/10.1111/ecc.13290>
- 613 8. Maringe C, Spicer J, Morris M, et al. The impact of the COVID-19 pandemic on cancer deaths due  
614 to delays in diagnosis in England, UK: a national, population-based, modelling study. *Lancet Oncol*.  
615 2020;21:1023-1034. [https://doi.org/10.1016/S1470-2045\(20\)30388-0](https://doi.org/10.1016/S1470-2045(20)30388-0)
- 616 9. International Pharmaceutical Federation (FIP) Health Advisory. Coronavirus SARS-CoV-2/ COVID-  
617 19 Pandemic: Information and interim guidelines for pharmacists and the pharmacy workforce 2020.  
618 [https://www.fip.org/files/content/priority-areas/coronavirus/Coronavirus-guidance-update-](https://www.fip.org/files/content/priority-areas/coronavirus/Coronavirus-guidance-update-ENGLISH.pdf)  
619 [ENGLISH.pdf](https://www.fip.org/files/content/priority-areas/coronavirus/Coronavirus-guidance-update-ENGLISH.pdf) Accessed September 11, 2020.
- 620 10. Ung COL. Community pharmacist in public health emergencies: Quick to action against the  
621 coronavirus 2019-nCoV outbreak. *Res Social Adm Pharm*. 2020;16:583-586.  
622 <https://doi.org/10.1016/j.sapharm.2020.02.003>
- 623 11. Visacri MB, Figueiredo IV, de Lima TM. Role of pharmacist during the COVID-19 pandemic: a  
624 scoping review. *Res Social Adm Pharm*. 2020. <https://doi.org/10.1016/j.sapharm.2020.07.003> Epub 4  
625 July 2020
- 626 12. Hughes CM, Hawwa AF, Scullin C, et al. Provision of pharmaceutical care by community  
627 pharmacists: a comparison across Europe. *Pharm World Sci*. 2010;32:472-487.  
628 <https://doi.org/10.1007/s11096-010-9393-x>
- 629 13. Cope LC, Abuzour AS, Tully MP. Nonmedical prescribing: where are we now? *Ther Adv Drug Saf*.  
630 2016;7:165-172. <http://doi.org/10.1177/2042098616646726>
- 631 14. Aly M, García-Cárdenas V, Williams K, Benrimoj SI. A review of international pharmacy-based  
632 minor ailment services and proposed service design model. *Res Social Adm Pharm*. 2018;14:989-  
633 998. <http://doi.org/10.1016/j.sapharm.2017.12.004>
- 634 15. Cadogan CA, Hughes CM. On the frontline against COVID-19: Community pharmacists'  
635 contribution during a public health crisis. *Res Social Adm Pharm*. 2020.  
636 <https://doi.org/10.1016/j.sapharm.2020.03.015> Epub 31 March 2020.
- 637 16. Equator Network. Consolidated criteria for reporting qualitative research (COREQ): a 32-item  
638 checklist for interviews and focus groups. <https://www.equator-network.org/reporting-guidelines/coreq/>  
639 Accessed September 11, 2020.



- 640 17. Stewart D, Paudyal V, Cadogan C, et al. A survey of the European Society of Clinical Pharmacy  
641 members' research involvement, and associated enablers and barriers. *Int J Clin Pharm*.  
642 2020;42:1073-1087. <https://doi.org/10.1007/s11096-020-01054-9>
- 643 18. European Association of Hospital Pharmacists. Who we are. [https://www.eahp.eu/about-us/who-](https://www.eahp.eu/about-us/who-we-are)  
644 [we-are](https://www.eahp.eu/about-us/who-we-are) Accessed September 11, 2020
- 645 19. Aruru M, Truong H-A, Clark S. Pharmacy emergency preparedness and response (PEPR)  
646 framework for expanding pharmacy professionals' roles and contributions to emergency  
647 preparedness and response during the COVID-19 pandemic and beyond. *Res Social Adm Pharm*.  
648 2020. <https://doi.org/10.1016/j.sapharm.2020.04.002> Epub 3 April 2020
- 649 20. Watson KE, Singleton JA, Tippett V, Nissen LM. Defining pharmacists' roles in disasters: A Delphi  
650 study. *PLoS One*. 2019;14. <https://doi.org/10.1371/journal.pone.0227132>
- 651 21. International Pharmaceutical Federation (FIP). Responding to disasters Guidelines for pharmacy  
652 2016. [https://www.fip.org/files/content/pharmacy-practice/military-emergency-pharmacy/emergency-](https://www.fip.org/files/content/pharmacy-practice/military-emergency-pharmacy/emergency-activities/2016-07-responding-to-disasters-guideline.pdf)  
653 [activities/2016-07-responding-to-disasters-guideline.pdf](https://www.fip.org/files/content/pharmacy-practice/military-emergency-pharmacy/emergency-activities/2016-07-responding-to-disasters-guideline.pdf) Accessed September 11, 2020
- 654 22. Ritchie J, Spencer L. Qualitative data analysis for applied policy research. *The qualitative*  
655 *researcher's companion*. 2002;573:305-329.
- 656 23. Hoti K, Jakupi A, Hetemi D, Raka D, Hughes J, Desselle S. Provision of community pharmacy  
657 services during COVID-19 pandemic: a cross sectional study of community pharmacists' experiences  
658 with preventative measures and sources of information. *Int J Clin Pharm*. 2020;42:1197-1206.  
659 <https://doi.org/10.1007/s11096-020-01078-1>
- 660 24. The New York Times. W.H.O. Fights a Pandemic Besides Coronavirus: An 'Infodemic'.  
661 <https://www.nytimes.com/2020/02/06/health/coronavirus-misinformation-social-media.html> Accessed  
662 September 11, 2020.
- 663 25. Koster ES, Philbert D, van Dijk L, et al. Recognizing pharmaceutical illiteracy in community  
664 pharmacy: Agreement between a practice-based interview guide and questionnaire based  
665 assessment. *Res Social Adm Pharm*. 2018;14:812-816.  
666 <https://doi.org/10.1016/j.sapharm.2018.01.009>
- 667 26. Erku DA, Belachew SA, Abrha S, et al. When fear and misinformation go viral: Pharmacists' role  
668 in deterring medication misinformation during the 'infodemic' surrounding COVID-19. *Res Social Adm*  
669 *Pharm*. 2020. <https://doi.org/10.1016/j.sapharm.2020.04.032> Epub 1 May 2020.
- 670 27. Larrouquere L, Gabin M, Poingt E, et al. Genesis of an emergency public drug information website  
671 by the French Society of Pharmacology and Therapeutics during the COVID-19 pandemic.  
672 *Fundamental & Clinical Pharmacology*. 2020;34:389–396. <https://doi.org/10.1111/fcp.12564>
- 673 28. General Pharmaceutical Council. How to complete your revalidation.  
674 <https://www.pharmacyregulation.org/revalidation-glance> Accessed September 09, 2020.
- 675 29. Kempen TGH, Kälve mark A, Sawires M, Stewart D, Gillespie U. Facilitators and barriers for  
676 performing comprehensive medication reviews and follow-up by multiprofessional teams in older  
677 hospitalised patients. *Eur J Clin Pharmacol*. 2020;76:775-784. [https://doi.org/10.1007/s00228-020-](https://doi.org/10.1007/s00228-020-02846-8)  
678 [02846-8](https://doi.org/10.1007/s00228-020-02846-8)
- 679 30. Niznik JD, He H, Kane-Gill SL. Impact of clinical pharmacist services delivered via telemedicine in  
680 the outpatient or ambulatory care setting: A systematic review. *Res Social Adm Pharm*. 2018;14:707-  
681 717. <https://doi.org/10.1016/j.sapharm.2017.10.011>
- 682 31. Crilly P, Kayyali R. A Systematic Review of Randomized Controlled Trials of Telehealth and  
683 Digital Technology Use by Community Pharmacists to Improve Public Health. *Pharmacy (Basel)*.  
684 2020;8:137. <https://doi.org/10.3390/pharmacy8030137>
- 685 32. Hadi MA, Closs SJ. Ensuring rigour and trustworthiness of qualitative research in clinical  
686 pharmacy. *Int J Clin Pharm*. 2016;38:641-646. <https://doi.org/10.1007/s11096-015-0237-6>

- 687 33. Donovan GR, Paudyal V. England's Healthy Living Pharmacy (HLP) initiative: Facilitating the  
688 engagement of pharmacy support staff in public health. *Res Soc Admin Pharm* 2016 12(2):281-92.  
689 doi: 10.1016/j.sapharm.2015.05.010.  
690
- 691 34. Paudyal V, Hansford D, Cunningham S et al. Community pharmacists' adoption of medicines  
692 reclassified from prescription-only status: a systematic review of factors associated with decision  
693 making. *Pharmacoepid Drug Saf* 2012 Apr;21(4):396-406. <https://doi.org/10.1002/pds.3219>  
694
- 695 35. Prescott GM, Vu BN, Alsharif NZ et al. Global Health Education in Doctor of Pharmacy Programs  
696 in the United States. *Am J Pharm Educ*. 2017;81:28. <https://dx.doi.org/10.5688%2Fajpe81228>  
697

698

Journal Pre-proof



**Table 1: Participant demographics**

<b>SN</b>	<b>Country</b>	<b>Practice setting</b>	<b>Speciality</b>	<b>Job title</b>	<b>Years qualified as a pharmacist</b>
1	Belgium	Hospital	Clinical pharmacy	Responsible clinical pharmacist	25
2	Croatia	Community pharmacy	Community pharmacy	Community pharmacist	16
3	Czech Republic	Hospital	Intensive Care Unit	Clinical pharmacist	19
4	Denmark	Hospital pharmacy	Hospital pharmacy	Head of hospital pharmacy	6
5	England	Primary care	Respiratory	Clinical pharmacist	21
6	England	Hospital pharmacy	Respiratory	Specialist clinical pharmacist	7
7	England	Community pharmacy	Community pharmacy/ Primary care	Manager/owner of a community pharmacy and part time in primary care	15
8	Estonia	Community pharmacy	Community pharmacy	Community pharmacist	3
9	France	Hospital	Hospital pharmacy	Pharmacist supervisor	20
10	France	Hospital	Hospital pharmacy	Hospital pharmacist	4
11	Republic of Ireland	Hospital	Cardiology and pharmacy management	Pharmacy education and research	28
12	Republic of Ireland	Community pharmacy	Community pharmacy	Superintendent and supervising	30
13	Italy	Hospital	Hospital pharmacy	Hospital pharmacist	8
14	Netherlands	Primary care	Elderly and polypharmacy	General practice pharmacist	9
15	Northern Ireland	Hospital	Cardiology	Senior hospital pharmacist	20
16	Portugal	Other	Consultancy- pharmaceutical care	Healthcare solutions designer	5
17	Serbia	Hospital	Liver transplant	Consultant clinical pharmacist	15
18	Serbia	Hospital	Orthopaedic surgery	Clinical pharmacist	16
19	Spain	Community pharmacy	Community pharmacy	Manager of a community pharmacy	28
20	Switzerland	Hospital	General hospital	Clinical pharmacist	5
21	Turkey	Hospital	Oncology	Clinical pharmacy Manager	10
22	Turkey	Hospital	Clinical Pharmacy	Clinical pharmacist Resident	3

Table 2 Thematic framework of analysis

Domain	Themes	Subthemes (where available)	Facilitators	Barriers
<b>Reducing the health risks posed by COVID-19</b>	Minimising the spread of COVID-19 in the workplace	Social distancing	-Organisational and estates arrangements to allow social distancing -Resources to build facilities in pharmacy to allow social distancing	-Physical facilities not allowing social distancing
		Risk stratification of patients in the clinical setting	-Availability of facilities to segregate patients as per risks	-
		Availability of PPE	-Availability of PPE	-Lack of access to good quality personal protective equipment -Lack of adequate personal protective equipment -Lack of resources to buy PPE
		Knowledge about correct use of PPE	-Training on how to use PPE	-Lack of training and knowledge about how to use PPE
		Sanitisation and hygiene practices	-Availability of chemicals and equipment for sanitisation	-Inadequate supply of sanitising chemicals
	Educating the public on reducing the spread of COVID-19	Actions undertaken to educate the public (such as provision of information around transmission risks)	-Resources to develop educational materials -Time to develop educational resources and provision of advice	-Lack of public acceptance of advice -False information available from other sources
<b>Preparedness</b>	Ensuring timely and effective response systems are in place	Adjustment of physical layout and infrastructure	-Organisational preparedness in adjusting clinical facilities -Availability of spaces to build temporary critical care units	-
	Maintaining safe staffing levels	Adjusting pharmacist distribution across clinical settings	-Readiness of pharmacists to practice in a new clinical setting	-Lack of training -Lack of knowledge and understanding of clinical

			<ul style="list-style-type: none"> <li>-Training to adapt new roles</li> <li>-Staff readiness to commit to new roles</li> <li>-Creation of new teams</li> <li>-Readiness to cover for new staff</li> </ul>	<ul style="list-style-type: none"> <li>procedures and drugs in a new setting</li> <li>-Lack of willingness to work from home</li> <li>-Lack of access to clinical records from home</li> </ul>
		Adjustment of leave and staff absences	<ul style="list-style-type: none"> <li>-provision of accommodation and shuttle services for staff</li> <li>-Flexibility to work from home</li> <li>-Remote access to clinical records when working from home</li> <li>-Government decisions to restrict opening hours of community pharmacy</li> </ul>	<ul style="list-style-type: none"> <li>-Burnout and fatigue</li> <li>-Difficulty sourcing locums</li> </ul>
		Getting students to help out	<ul style="list-style-type: none"> <li>-Availability of space to accommodate students</li> </ul>	<ul style="list-style-type: none"> <li>-Social distancing measures limiting the number of staff in a clinical setting</li> </ul>
	Testing staff for Covid-19	Access and availability of COVID-19 test facilities	<ul style="list-style-type: none"> <li>-Early testing and isolation practices</li> </ul>	<ul style="list-style-type: none"> <li>-Lack of access to testing</li> </ul>
<b>Action-response and adjustment</b>	Ensuring uninterrupted supply of medications and ensuring business continuity plans	Sourcing and ordering medicines	<ul style="list-style-type: none"> <li>-Government support to source medicines</li> <li>-Good procurement services in the clinical setting</li> <li>-Ordering medicines to ensure business continuity</li> </ul>	<ul style="list-style-type: none"> <li>-Lack of availability of medicines for intensive care medicine</li> </ul>
		Rationing of medicines and medical supplies	<ul style="list-style-type: none"> <li>-Time and resource to repackage and label</li> <li>-Availability of alternative brands and products</li> <li>-Patient acceptance of alternative brands and smaller pack sizes</li> </ul>	-
		Making therapeutic substitutions	<ul style="list-style-type: none"> <li>-Doctor's acceptance of therapeutic substitutions</li> </ul>	-
		Extending repeat prescriptions without	<ul style="list-style-type: none"> <li>-Flexibility in legislations to allow special supply</li> </ul>	<ul style="list-style-type: none"> <li>-Lack of availability of medicines to ensure seamless supply</li> </ul>

	doctors' agreements	provisions	
Impact and adjustment of routine clinical practice	Low use of healthcare services by patients	-	-Patient fears about the use of healthcare settings
	Cancelled elective appointments in hospitals	-	-Patient fears about the use of healthcare settings
	Interruption to routine clinical pharmacy services such as blood pressure checks and cholesterol testing	-Patient acceptance and understanding to reduced services	-Lack of coordination between primary care and community pharmacy -Lack of ability to conduct appropriate monitoring of disease and medicines use
	Offering home testing kits for disease monitoring	-Patient resources to buy home testing kits	-
	Providing care plan for the patients to care at home	-Family/carer support for patients at home	-
	Communicating with patients and healthcare professionals	Use of telephone, video and social media	-Availability of appropriate digital platform
Ensuring effective remote communications		-Patient access to digital platforms -Patient confidence to use digital platform -Family and carer support to patients for the use of digital platform	-Patient lack of access to digital platform -Patients with reduced cognitive states facing difficulty with digital platforms -Lack of time to set up digital communications -Difficulty persuading patients to adhere to their medicines when communicating remotely
Barriers to effective communications due to PPE		-	-Interference with voice and body language due to pharmacist use of PPE

				-Patients with sensory disabilities, different first language and reduced cognitive functions not able to understand masked communications
		Impact on inter-professional communications	-	-Reduced rate of acceptance of pharmacists' interventions when made remotely (compared to face to face)
Advocating pharmacy's role and being source of information to doctors	Searching and appraising information and evidence		-Access to online resources and journals	-
	Professional role and identity		-Recognition of pharmacists' expertise and knowledge by senior management and other healthcare professionals -Use of same uniform and PPE by all healthcare professional leading to lack of professional hierarchy	-Lack of recognition of pharmacists' expertise and knowledge by senior management and other healthcare professionals
Taking care of COVID-19 patients	Sourcing and appraising information		-Access to online resources and journals	-
	Availability and access to guidelines from professional societies and public health agencies		-Availability of clinical guidelines -Availability of training opportunities and webinars -Access to peer reviewed journals	-Mismatch of information across guidelines -Conflicting advice from various clinical disciplines in practice
	Monitoring safety and effectiveness of new drugs		-Ability to monitor patients on new drugs	-Lack of knowledge about the experimental drugs
<b>Recovery and returning to normal</b>	Sustainability of social distancing measures	-	-Benefits to high risk patients such as in transplant care	-

	Greater use of technology in communications and clinical care	-	-Availability of effective and efficient digital platforms	-
	Extended roles for pharmacy profession	--	-Other healthcare professionals' recognition and acceptance of pharmacists' clinical roles -Patient reluctance to use general practice services -Pharmacists' confidence to offer extended services	-
	Readiness to offer vaccination for COVID-19	-	-Pharmacists' readiness to deliver new services	-
<b>Reflection of personal experience, attitudes and behaviours</b>	Personal experiences and coping strategies	-	-Pride in serving patients and humanity -Professional pride -Being able to help others -Being able to look after each other in the healthcare team	-
	Motivation	-	-Professional pride -Service to humanity -Seeing COVID-19 patients discharged and returning home -Looking after patients and each other -Effective clinical leadership	-
	Measuring successes and failures	-	-Being able to measure patient outcomes -Being able to keeping themselves and staff safe	-Lack of benchmarks to measure successes or failures
	Knowledge and skills learnt [e.g. - critical care,	-	-Readiness of pharmacists to practice new skills and in a new clinical setting	-Lack of recognition of pharmacists' skills and expertise from other healthcare

	extemporaneous dispensing, use of telecommunications and telemedicine, clinical trials, resilience and adaptability]			professionals
--	--	--	--	---------------

COVID-19: Coronavirus Disease; PPE: Personal Protective Equipment

Journal Pre-proof

**Table 3: Recommendations for health systems and pharmacy services****Prevention**

1. Government and healthcare agencies should make adequate provision of PPEs and sanitising chemicals
2. Government and healthcare agencies should prepare pharmacists to provide training on correct use of PPEs to other healthcare staff
3. Government and healthcare agencies should promote pharmacists to develop and disseminate evidence based information to the general public and patients about control measures and mitigating the risks of pandemic
4. Education of pharmacists in the professional pharmacy curriculum should incorporate aspects of prevention and mitigation of pandemics

**Preparedness**

1. Pharmacists should be given key decision making roles in relation to stratification of risks in clinical areas
2. Pharmacists in diverse clinical settings should receive training to deliver pharmaceutical care services in critical care areas in preparedness of the pandemic
3. Pharmacists' expertise and skills should be harnessed to enable them source and critically appraise evidence based information i
4. Pharmacists should receive adequate continuous professional development opportunities to source and appraise evidence based information
5. Healthcare services should identify measures to ration clinical pharmacy services to address staff shortages during the time of pandemic
6. Government and healthcare agencies should build strategies around how to best use student pharmacist resources at the time of pandemic

**Action-response**

1. Pharmacists should be trained to enable efficient procurement practices to ensure adequate supply of medicines
2. Government and healthcare agencies should utilise clinical pharmacists in gathering intelligence around the list of medicines that are likely to face shortages at the time of pandemic and ensure adequate planning to counter shortages
3. Pharmacists should be trained to enable therapeutic substitutions at the time of medicines shortages
4. Government and healthcare agencies should promote the potential clinical pharmacy can offer during the time of pandemic
5. Government and healthcare agencies should provide resources to pharmacists to ensure clinical pharmacy services are not interrupted at the time of pandemic, such as sourcing additional staff, customising facilities and availability of equipment to monitor disease status and drug safety and effectiveness
6. Remote means of communications and telemedicine need to be strengthened to allow better and effective communications between pharmacists and patients as well as other health care professionals.
7. Remote means of communications and telemedicine should cater for patients with low literacy, low cognitive functions, elderly and those with the need for language interpretation



8. Novel technologies should be harnessed to facilitate effective communications while pharmacists are on PPE
9. Government and healthcare agencies should utilise pharmacists in the delivery of vaccinations and new medicines to provide protection and treatment
10. Pharmacists routine activities such as dispensing of medicines, minor ailments services and prescribing activities should be harnessed to ensure clinical services provision from diverse settings
11. Government and healthcare agencies should ensure that the new knowledge and skills gained during the pandemic should be maintained and passed on to new practitioners

PPE: Personal Protective Equipment

### Highlights

- Clinical pharmacists in diverse settings adapted current services and adopted novel roles during the COVID-19 pandemic
- Clinical pharmacists facilitated clinical trials, gathered and appraised evidence and disseminated information to patients and other healthcare professionals
- Pharmacists ensured uninterrupted supply of medicines through innovation and provided frontline advice to patients
- Routine clinical services were extensively interrupted and remote forms of communication were used
- Barriers to prevention, preparedness and response actions to pandemic needs to be addressed by governments and health systems